National Institute for Clinical Excellence (NICE) Rejects Pfizer Inc.'s Bone Cancer Drug

Published: Jul 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The UK National Institute for Health and Care Excellence (NICE) has rejected Pfizer’s new chronic myeloid leukaemia (CML) drug, Bosulif (bosutinib).

NICE chief executive Sir Andrew Dillon said there is evidence to suggest that bosutinib was considered clinically effective for the treatment of CML.

Help employers find you! Check out all the jobs and post your resume.

Back to news